Business Description
Ionis Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US4622221004
Compare
Compare
Traded in other countries / regions
IONS.USAISI.Germany0JDI.UKIONS.Mexico IPO Date
1991-05-17Description
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019).
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 1.6 | |||||
| Equity-to-Asset | 0.13 | |||||
| Debt-to-Equity | 3.76 | |||||
| Debt-to-EBITDA | -6.16 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | 1.44 | |||||
| Beneish M-Score | -0.66 | |||||
| WACC vs ROIC | ||||||
Growth Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 1.7 | |||||
| 3-Year EBITDA Growth Rate | -27.4 | |||||
| 3-Year EPS without NRI Growth Rate | 2.8 | |||||
| 3-Year FCF Growth Rate | -298.6 | |||||
| 3-Year Book Growth Rate | -20.3 | |||||
| Future 3-5Y Total Revenue Growth Rate | 12.9 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 57.66 | |||||
| 9-Day RSI | 48.85 | |||||
| 14-Day RSI | 46.07 | |||||
| 6-1 Month Momentum % | -8.21 | |||||
| 12-1 Month Momentum % | 19.81 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 5.9 | |||||
| Quick Ratio | 5.83 | |||||
| Cash Ratio | 5.2 | |||||
| Days Inventory | 989.77 | |||||
| Days Payable | 672.07 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -0.9 | |||||
| Shareholder Yield % | -3.7 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 98.84 | |||||
| Operating Margin % | -44.91 | |||||
| Net Margin % | -46.5 | |||||
| FCF Margin % | -42.97 | |||||
| ROE % | -83.63 | |||||
| ROA % | -12.79 | |||||
| ROIC % | -73.29 | |||||
| ROC (Joel Greenblatt) % | -101.18 | |||||
| ROCE % | -10.25 | |||||
| Years of Profitability over Past 10-Year | 3 |
GF Value Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 7.72 | |||||
| PB Ratio | 15.85 | |||||
| Price-to-Tangible-Book | 15.85 | |||||
| EV-to-EBIT | -20.55 | |||||
| EV-to-Forward-EBIT | -9.5 | |||||
| EV-to-EBITDA | -22.51 | |||||
| EV-to-Forward-EBITDA | -9.78 | |||||
| EV-to-Revenue | 6.74 | |||||
| EV-to-Forward-Revenue | 8.73 | |||||
| EV-to-FCF | -15.82 | |||||
| Price-to-Projected-FCF | 8.19 | |||||
| Price-to-Median-PS-Value | 0.67 | |||||
| Price-to-Net-Current-Asset-Value | 155.96 | |||||
| Earnings Yield (Greenblatt) % | -4.87 | |||||
| FCF Yield % | -5.42 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Ionis Pharmaceuticals Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 728.505 | ||
| EPS (TTM) (€) | -2.387 | ||
| Beta | -0.16 | ||
| Volatility % | 30.45 | ||
| 14-Day RSI | 46.07 | ||
| 14-Day ATR (€) | 0.551242 | ||
| 20-Day SMA (€) | 39.4495 | ||
| 12-1 Month Momentum % | 19.81 | ||
| 52-Week Range (€) | 31.29 - 49 | ||
| Shares Outstanding (Mil) | 145.75 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Ionis Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Ionis Pharmaceuticals Inc Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Ionis Pharmaceuticals Inc Frequently Asked Questions
What is Ionis Pharmaceuticals Inc(FRA:ISI)'s stock price today?
The current price of FRA:ISI is €38.99. The 52 week high of FRA:ISI is €49.00 and 52 week low is €31.29.
When is next earnings date of Ionis Pharmaceuticals Inc(FRA:ISI)?
The next earnings date of Ionis Pharmaceuticals Inc(FRA:ISI) is 2024-05-07.
Does Ionis Pharmaceuticals Inc(FRA:ISI) pay dividends? If so, how much?
Ionis Pharmaceuticals Inc(FRA:ISI) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers